SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigation of Eidos Therapeutics, Inc. Buyout

WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos' agreement to be acquired by BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ GS: BBIO).  Under the terms of the agreement, Eidos' shareholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash per share.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-eidos-therapeutics-inc.     

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:                                                                                             

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com

SOURCE Rigrodsky & Long, P.A.

Related Links

http://www.rigrodskylong.com